The global respiratory virus vaccines market size is projected to hit around US$ 14.6 billion by 2030 from US$ 2.7 Bn in 2020, growth is expanding at a CAGR of 8.1% from 2021 to 2030.
Rise in prevalence of respiratory illnesses and demand for newer vaccines for the prevention of respiratory infections, and large number of pharmaceutical companies participating in the race to develop vaccine for the novel coronavirus are major factors projected to boost the respiratory virus vaccines market during the forecast period.
A vaccine is a biological preparation that is used to provide acquired immunity against numerous harmful pathogens. It is administered in order to prevent the vulnerable population against specific disease. It contains an agent, i.e. bacteria or virus strain, which causes a particular disease in a weakened or killed form.
Immunization Programs Significantly Reduce Mortality Rates for Measles
The World Health Organization (WHO) claims that immunization has become an important tool for innovation in measles vaccines. With the help of immunization, several million infants are being vaccinated against measles, thus lowering mortality rates worldwide. Companies in the respiratory virus vaccines market are developing promising vaccines that protect the health of individuals from tuberculosis and influenza. They are intensifying their R&D capabilities to develop neutralizing antibodies and therapeutic respiratory virus vaccines that can generate value-grab opportunities for manufacturers.
There is a growing demand for needle-free vaccine administration to suit the needs of adolescents, pregnant women, and other age groups. Moreover, there is a need for robust vaccine storage and supply chains that hold promising potentials to transform immunization programs in the upcoming decade. Thus, timely access to reliable data is found to provide exciting opportunities for companies in the respiratory virus vaccines market.
Large Investments Play Key Role in Validated Efficacy of Mumps Vaccines
A research done by Emory Vaccine Center and the Centers for Disease Control and Prevention indicates that immunity against mumps virus appears to be insufficient among a fraction of college-aged individuals who were previously vaccinated in their childhood. Thus, companies in the respiratory virus vaccines market are increasing efforts to better understand the immune response to mumps and mumps vaccines. In the past decade, it has been observed that several mumps outbreaks have occurred among sports teams, college students, and close-knit communities in the U.S. Hence, pharmaceutical companies are focusing on developing effective mumps vaccines to lower the rate of mumps outbreaks.
Lack of strong immune response pertaining to mumps vaccine has emerged as a challenge for companies in the respiratory virus vaccines market. Manufacturers are directing large investment in clinical trials to demonstrate the safety and efficacy of mumps vaccines.
In terms of type, the global respiratory virus vaccines market has been classified into inactivated/killed vaccines, live-attenuated vaccines, and recombinant vaccines. The inactivated/killed vaccines segment accounted for a prominent share of the global market in 2020. The segment is estimated to be driven by the launch of new vaccines and robust research programs for the development of inactivated vaccine for COVID-19.
Based on route of administration, the global respiratory virus vaccines market has been categorized into intramuscular, intranasal, and subcutaneous. The intramuscular segment held a major share of the global market in 2019.
In terms of indication, the global respiratory virus vaccines market has been classified into influenza, measles, mumps & rubella, coronavirus disease (COVID-19), and others. The influenza segment held a notable share of the global market in 2020. The segment is likely to be driven an increase in number of influenza patients and a rise in focus on vaccination programs for children.
Based on age group, the global respiratory virus vaccines market has been divided into pediatric and adults. The pediatric segment accounted for a leading share of the global market in 2020.
In terms of end user, the global respiratory virus vaccines market has been classified into physician’s office, hospitals, clinics, pharmacies/stores, and others. The physician’s office segment held a significant share of the global market in 2020.
By geograpghy, the North America held a major share of the global respiratory virus vaccines market in 2020. Increase in demand for effective vaccination, rise in number of patients with influenza, and favourable government support for adult and pediatric vaccination are key factors driving the market in the region. According to the Centers for Disease Control and Prevention (CDC), seasonal influenza accounts for over 20,000 deaths in the U.S. each year.
Europe held the second-largest share of the global respiratory virus vaccines market in 2020. The expansion of the respiratory virus vaccines market in the region can be attributed to increase in investment in R&D activities to develop vaccine against the novel coronavirus through partnerships between pharmaceutical companies.
This section of the report identifies various key manufacturers of the market. It helps the reader understand the strategies and collaborations that players are focusing on combat competition in the market. The comprehensive report provides a significant microscopic look at the market. The reader can identify the footprints of the manufacturers by knowing about the global revenue of manufacturers, the global price of manufacturers, and sales by manufacturers during the forecast period of 2017 to 2019.
The analysts have provided a comprehensive analysis of the competitive landscape of the global respiratory virus vaccines market with the company market structure and market share analysis of the top players. The innovative trends and developments, mergers and acquisitions, product portfolio, and new product innovation expected to provide a dashboard view of the market, ultimately providing the readers accurate measure of the current market developments, business strategies, and key financials.
Major manufacturers & their revenues, percentage splits, market shares, growth rates and breakdowns of the product markets are determined through secondary sources and verified through the primary sources.
Top-down and bottom-up approaches are used to estimate and validate the global market size for company, regional division, product type and application (end users) and other segments.
Key players operating in the global respiratory virus vaccines market include CSL Limited, Sanofi, AstraZeneca, Merck & Co., Inc., GlaxoSmithKline plc, Serum Institute of India Pvt. Ltd., Bharat Biotech, and Sinovac Biotech Ltd.
By Route of Administration
By Age Group
By End User
This report focuses on respiratory virus vaccines market includes crucial information on market share, market size, and growth rate for the forecast period 2021 to 2030 at the global level, regional level and company level. From a global perspective, this report represents overall respiratory virus vaccines market size by analyzing historical data and future prospect. The study highlights deep analysis on the major drivers of the market, restraints, and challenges to help the business owners, suppliers, and marketing personnel in planning effective strategies for the forecast period. This will help the business and manufacturers to lead the market and gain prominent position in future. The report also presents vital information through graphical representation on factors like table, charts, and statistics. The study includes drivers and restraints of the global respiratory virus vaccines market.
The research not only conducts forecasts in terms of value, but also evaluates the market on the basis of essential parameters, such as Year-on-Year (Y-o-Y) growth. This helps providers to recognize the future opportunities as well predictability of the market.
In order to understand and assess opportunities in this market, the report is categorically divided into five key sections on the basis of segments. The report analyzes the global market in terms of value (US$ dollers) and volume (Million Units).
The research report includes specific segments by region (country), by company, by all segments. This study provides information about the growth and revenue during the historic and forecasted period of 2017 to 2030. Every segment is further sub-segmented into several sub-segmented that are deeply analyzed by experts to offer valuable information to the buyers and market players. Understanding the segments helps in identifying the importance of different factors that aid the market growth.
The research report includes a detailed study of regions of North America, Europe, China, Japan and Rest of the World. The report has been curated after observing and studying various factors that determine regional growth such as economic, environmental, social, technological, and political status of the particular region. Analysts have studied the data of revenue and manufacturers of each region. This section analyses region-wise revenue and volume for the forecast period of 2017 to 2030. These analyses will help the reader to understand the potential worth of investment in a particular region.
The report provides in-depth segment analysis of the global respiratory virus vaccines market, thereby providing valuable insights at macro as well as micro levels. Analysis of major countries, which hold growth opportunities or account for significant share has also been included as part of geographic analysis of the respiratory virus vaccines market.
The report includes country-wise and region-wise market size for the period 2017-2030. It also includes market size and forecast by segments in terms of production capacity, price and revenue for the period 2017-2030.
In this study, the years considered to estimate the market size of respiratory virus vaccines are as follows:
The research methodology adopted by analysts for compiling the global respiratory virus vaccines market report is based on detailed primary as well as secondary research. With the help of in-depth insights of the market-affiliated information that is obtained and legitimated by market-admissible resources, analysts have offered riveting observations and authentic forecasts for the global market.
During the primary research phase, analysts interviewed market stakeholders, investors, brand managers, vice presidents, and sales and marketing managers. Based on data obtained through interviews of genuine resources, analysts have emphasized the changing scenario of the global market.
For secondary research, analysts scrutinized numerous annual report publications, white papers, market association publications, and company websites to obtain the necessary understanding of the global respiratory virus vaccines market.
The study objectives of this report are:
Trauma Care Centers Market (By Facility Type: In-house, Standalone; By Trauma Type: Falls, Traffic-related Injuries; By Service Type) - Global Industry Analysis, Size, Share, Growth, Trends, Revenue, Regional Outlook and Forecast 2022-2030Read more...
Monkeypox Vaccine And Treatment Market (By Product: Vaccine, Drugs) - Global Industry Analysis, Size, Share, Growth, Trends, Revenue, Regional Outlook and Forecast 2022-2030Read more...
Hyaluronic Acid Market (By Application: Dermal Fillers, Osteoarthritis, Ophthalmic, Vesicoureteral Reflux) - Global Industry Analysis, Size, Share, Growth, Trends, Revenue, Regional Outlook and Forecast 2022-2030Read more...
AI in Oncology Market (By Treatment: Chemotherapy, Radiotherapy, Immunotherapy, Targeted Therapy, Gene Therapy; By Cancer Type; By Application) - Global Industry Analysis, Size, Share, Growth, Trends, Revenue, Regional Outlook and Forecast 2022-2030Read more...
Paracetamol IV Market (By Application: Surgical, Non-surgical; By Indication: Pyrexia, Pain; By End-use: Hospitals, Clinics) - Global Industry Analysis, Size, Share, Growth, Trends, Revenue, Regional Outlook and Forecast 2022-2030Read more...